Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03081468
Other study ID # 16/0578
Secondary ID
Status Completed
Phase
First received March 10, 2017
Last updated April 5, 2018
Start date May 18, 2017
Est. completion date November 30, 2017

Study information

Verified date April 2018
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In current, clinical ophthalmology, a range of specialised testing allows comprehensive evaluation of ocular health. These tests have typically evolved over many years to ensure their clinical validity. For example, the assessment of visual acuity has traditionally been measured with Snellen letter charts from a distance of six metres (20 feet), leading to the phrase "20/20 vision". Despite this, the limitations of Snellen testing are well established and more sophisticated testing is now available (e.g., logMAR testing using ETDRS (Early Treatment Diabetic Retinopathy Study) charts). Many other diagnostic tests have undergone similar cycles of refinement, often over extended time periods. Therefore, it should be incumbent on any new device to undergo detailed evaluation of its validity (how its measurements agree with other testing) and its repeatability (the variability when a further measurement is obtained in short time period, by the same operator and under the same conditions).

Binocular OCT extends the application of OCT devices beyond that of simple, cross- sectional imaging to a diverse array of diagnostic tests. The binocular design also removes the need for additional personnel to perform testing (i.e., the device can be self-operated in an automated manner), and allows for novel testing to be performed that is not possible with monocular imaging. In particular, binocular OCT devices have the potential to perform automated, quantitative pupillary measurements - an entirely novel application for this imaging modality.

This study will assess the validity and repeatability of pupil measurements using binocular OCT.


Description:

Binocular OCT has the potential to allow for objective, quantitative measurement of pupillary reflexes, that can be performed in a fast, safe, and automated manner. Importantly, binocular OCT pupillometry can be performed alongside binocular retinal OCT imaging in a single testing session, in an automated manner (imaging of the retina using OCT is the commonest ophthalmic imaging procedure worldwide - in 2011, it is estimated that more than 20 million retinal OCT images were obtained, more than the sum of all other ophthalmic imaging procedures combined).

Assessment of pupillary reflexes is an essential component of a comprehensive ocular examination. In patients with visual loss, for example, detection of an RAPD often indicates the presence of serious ophthalmic diseases, such as optic neuropathies or severe retinal disease. As such, RAPD testing is essential as a screening test in the assessment of patients with less serious conditions such as cataract.

RAPD testing is commonly performed using the swinging flashlight method (SFM). A positive SFM test suggests the presence of asymmetric damage involving the afferent limb of the pupillary light reflex pathway. The SFM is a qualitative test, and relies upon visualising no pupillary constriction or immediate or delayed pupillary dilation; if either of these responses is observed, an RAPD is believed to be present. The SFM requires a trained examiner and many potential sources of error may confound the results, including anisocoria, off-axis pupil illumination, and unequal retinal bleaching. Pupil abnormalities may be subtle and easily missed using the SFM.

Automated pupilometers allow examiners to precisely and objectively quantify the pupillary response to light by measuring parameters such as minimum and maximum pupil diameter, the amplitude of constriction, latency of constriction, velocity of constriction, and duration of maximum constriction. Dedicated pupillometry devices are commercially available and have been shown to be highly sensitive and specific for RAPD detection e.g. RAPDx; Konan Medical USA, Inc., Irvine, CA. These devices are also capable of detecting the presence of more subtle RAPD, typically not found using the SFM, in diseases such as glaucoma.

Unfortunately, automated pupilometers such as the Konan RAPDx system are not widely used in clinical practice. This is largely because they are expensive devices, limited to a single purpose. A binocular OCT system that could perform both automated pupillometry and retinal OCT imaging would thus have great clinical utility.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date November 30, 2017
Est. primary completion date November 30, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for participants with eye disease will include:

- Presence of RAPD as measured with RAPDx

- Presence of retinal disease, glaucoma or neuro-ophthalmic conditions that affect the optic nerve

- Male or female, aged 18 years or older

- Ability to understand nature/purpose of the study and to provide informed consent

- Ability to undergo binocular OCT imaging

- Ability to follow instructions and complete the study

- Ability to speak English

Exclusion criteria for participants with eye disease will include:

- Optical media opacity sufficient to preclude adequate ocular imaging with OCT

- Ptosis (drooping of the upper eyelid) sufficient to preclude visualization of the pupils using OCT

- Significant pupil irregularity that precludes reliable measurement of RAPD

- Any condition that is likely to interfere with pupillary constriction (e.g., iris pathology)

- Hearing impairment sufficient to interfere with hearing instructions

- Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct.

Inclusion criteria for healthy subjects will include:

- No self-reported ocular history (although wearing corrective prescription glasses is permitted)

- Male or female, aged 18 years or older

- Ability to understand nature/purpose of the study and to provide informed consent

- Ability to undergo binocular OCT imaging

- Ability to follow instructions and complete the study

- Ability to speak English

Exclusion criteria for healthy subjects will include:

- Presence of ocular pathology, including ptosis or pupil irregularities

- Hearing impairment sufficient to interfere with hearing instructions

- Any condition which, in the investigator's opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule, or other study conduct.

Study Design


Intervention

Device:
Binocular OCT prototype
Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
Konan RAPDx
Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).

Locations

Country Name City State
United Kingdom Moorfields Eye Hospital NHS FT London

Sponsors (1)

Lead Sponsor Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of the binocular OCT The primary objective will be to determine the diagnostic accuracy of a prototype binocular OCT system for the detection of relative afferent pupillary defect (RAPD). 6 months
Secondary Test-retest variability of the binocular OCT pupillometry assessment The secondary objective will be to assess the repeatability (test-retest variability) of pupillary assessment using this prototype binocular OCT system. 6 months
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1